Search PubMed⌕ Search

Biomedical subjects

M Thiery

Publications and source records attributed to M Thiery.

At least 163 records · Page 9Linked to original sources
PubMed1982

Copper loss from the copper T model TCu22OC.

The effect of mineral deposits on the copper dissolution rate of the Copper T Model TCu22OC was examined. 118 Copper T22OC devices removed from subjects for various medical and personal reasons after 12 to 72 months in utero were examined and graded based on the proportion of the total copper area covered with mineral deposits. The deposits increased in average size during the first three years of IUD use and then remained relatively constant. Seventeen percent of the devices were in situ for four or more years. Copper analysis was performed on 30 Copper T 22OC devices from selected periods of use : 12-14, 22-26, 36-39 and 48-72 months of use. The mean daily copper loss was 29.4 micrograms and the range, 7.3 to 62.1 micrograms. An inverse correlation between the amount of mineral deposit on the copper surface and the rate of copper loss was observed.

Copper↗
PubMed1982

Metabolic effects of the triphasic oral contraceptive Trigynon.

Effects of Trigynon, a triphase low-dose oral contraceptive, containing ethinylestradiol and l-norgestrel in various proportions, on testosterone binding globulin, transcortin, thyroxine, free testosterone, free cortisol and free thyroxine as well as on plasma lipids and glucose tolerance were studied in 12 normal women treated for 3-6 months. Trigynon appears to have dominant estrogenic effects as evidenced from the increase in transport proteins and the decrease in free testosterone concentration. Plasma lipids were not significantly influenced; glucose tolerance was slightly, but not significantly decreased.

Adult↗
PubMed1982

The ML Cu250; clinical experience in Belgium and The Netherlands.

The ML Cu250, a copper-wired intrauterine contraceptive device, was inserted in 5736 women, at interval or immediately after delivery of the placenta. Forty-eight months after insertion, the data covering 196 214 woman-months were computerized and then analysed according to the life-table method. Interval insertion was more effective than postplacental insertion. In nulligravidas interval insertion did not increase the removal rates for other medical reasons (including pelvic inflammatory disease), but expulsion rates were higher relative to the entire group (a variety of parities).

Belgium↗
PubMed1982

Perinatal effects of cervical vibration.

Possible perinatal effects of elective cervical vibration during first-stage labor were studied in 20 subjects. Assessment of fetal status was based on biophysical and biochemical methods, whereas at birth the infant was evaluated clinically and biochemically. With the reservation required by the small sample it is concluded that cervical vibration by itself is perinatally safe.

Acid-Base Equilibrium↗
PubMed1982

Use of chloroprocaine for obstetric analgesia.

The effects of low concentration chloroprocaine in continuous lumbar epidural analgesia during labor and delivery, were evaluated in 21 subjects. The final analysis was made on 18 parturientis, 9 receiving 1.5% (group A) and 9 1.33% chloroprocaine (group B), in a standard dose of 7-8 ml (first test dose 2-3 ml), and of 12 ml for the second stage of labor. Onset of analgesia occurred 7.4 +/- 1.2 (mean +/- S.D.) (group A) and 9.6 +/- 1.8 min. (group B) after injection (difference significant). Mean interval between first and second doses was 50.5 +/- 6.3 (group A) and 47.5 +/- 10.8 (group B) min. (difference N.S.). In group A 6 patients and in group B only 1 patient had a temporarily decrease in bloodpressure below 100 mm Hg. During routine monitoring, pathological F.H.R. patterns were recorded in 2 cases. Apgar scores and acid-base parameters were within normal limits in both groups (difference N.S.).

Adult↗
PubMed1981

Plasma levels of ethinylestradiol (EE) during cyclic treatment with combined oral contraceptives.

The purpose of the present study was to extend the still limited data concerning ethinylestradiol (EE) plasma levels after repeated daily ingestion of a combination pill during the course of classical cyclic treatment. Plasma EE levels were followed in 13 volunteers throughout, in total, 19 treatment cycles with either a 50 ug EE (+ 125ug d-norgestrel) or a 30 ug (+ 150ug d-norgestrel) containing oral contraceptive. In addition, single plasma EE determinations were performed in 110 chronic oral contraceptive users. Whereas different patterns in plasma EE levels (sampling 24 hours following last pill ingestion) were observed among the different volunteers, the mean levels increased progressively during treatment and reflected closely the differences in dosage. The values obtained in the volunteers at the end of the treatment cycle showed important interindividual variations. The findings during a first treatment cycle or during the following ones were similar and for different treatment cycles in the same patient, the patterns in plasma EE levels were consistent. The results for single plasma determinations in chronic contraceptive users (sampling between 8th and 21st day of treatment cycle, 9 to 24 hours since last pill ingestion) showed more pronounced interindividual variations, the individual EE levels being not correlated to parameters such as body weight, body surface, months of oral contraception prior to the study, sex hormone binding capacity or day of the cycle. However, significant differences in mean plasma EE levels were noticed for patients treated with different commercial preparations with identical EE content, suggesting the existence of differences in bioavailability. The relevancy of plasma EE determinations is discussed and from the results of the present study, it is concluded that a strictly standardized time of sampling is an absolute condition for obtaining interpretable results.

Contraceptives, Oral↗
PubMed1981

Prostaglandins for the management of anencephalic pregnancy.

In 17 women carrying an anencephalic fetus (3 or them dead) an attempt was made to terminate the pregnancy with either intravaginal suppositories containing 20 mg prostaglandin E2 each or serial intramuscular injections of 250 microgram of 15(S)-15-methyl-prostaglandin F2 alpha. The duration of pregnancy ranged from 18 to 39 weeks (mean: 28.5 weeks). Fifteen women expelled the complete uterine contents after a period ranging from 4:15 to 39:10 h:min (mean: 15:11 h:min) following the initiation of treatment. There were two failures, and in both of these cases labor started spontaneously after cessation of the prostaglandin treatment. No serious complications occurred. The PG treatment induced no changes in routine laboratory values and significant alterations in the mother's vital signs were uncommon. Even though intravaginal prostaglandin E2 and intramuscular 15-methyl-prostaglandin F2 alpha often produced gastro-intestinal side effects, there can be no doubt as to the unique utility of these compounds for the management of anencephalic pregnancies, whatever the duration of gestation and vital status of the fetus.

Abortion, Therapeutic↗